SCHEMBL25950787

SCHEMBL25950787

c1ccc(-c2cccc(-c3ccccc3-c3nc(-c4ccc5c(c4)oc4ccccc45)nc(-c4cccc5sc6ccccc6c45)n3)c2)cc1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP12 P39900 1/20 0.34
MMP13 P45452 1/20 0.34
PRKDC P78527 2/20 0.34
PLA2G2A P14555 3/20 0.34
PLA2G4A P47712 3/20 0.34
ALOX5 P09917 2/20 0.33
HCRTR1 O43613 1/20 0.33
BRDT Q58F21 1/20 0.32
PLA2G10 O15496 1/20 0.32
AHR P35869 1/20 0.32
MEN1 O00255 2/20 0.31
ALDH1A1 P00352 2/20 0.31
KMT2A Q03164 2/20 0.31
F9 P00740 1/20 0.31
POLB P06746 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
KDM4E B2RXH2 1/20 0.31
MAPT P10636 1/20 0.31
HPGD P15428 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25945019 0.97 MMP12 (0.36) MMP12MMP13PRKDCPLA2G2APLA2G4A
SCHEMBL25645782 0.97 MMP12 (0.36) MMP12MMP13PRKDCPLA2G2APLA2G4A
SCHEMBL26080459 0.97 MMP12 (0.36) MMP12MMP13PRKDCPLA2G2APLA2G4A
SCHEMBL26080480 0.96 F9 (0.34) MMP12MMP13PRKDCPLA2G2APLA2G4A
SCHEMBL26080457 0.96 MMP12 (0.35) MMP12MMP13PRKDCPLA2G2APLA2G4A
SCHEMBL19802831 0.94 PLA2G2A (0.33) MMP12MMP13PRKDCPLA2G2APLA2G4A
SCHEMBL26080473 0.94 PLA2G2A (0.37) PRKDCPLA2G2APLA2G4AALOX5BRDT
SCHEMBL25645671 0.94 HCRTR1 (0.36) MMP12MMP13PRKDCPLA2G2APLA2G4A
SCHEMBL26080487 0.94 F9 (0.34) MMP12MMP13PRKDCALOX5HCRTR1
SCHEMBL25645779 0.94 MMP12 (0.34) MMP12MMP13PRKDCPLA2G2APLA2G4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230312538-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME LT MATERIALS CO., LTD. (KR) 2023-10-05 US disclosed
US-20230312538-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME LT MATERIALS CO., LTD. (KR) 2023-10-05 US disclosed
EP-4212526-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME LT Materials Co., Ltd. (KR) 2023-07-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230312538-A1 HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE COMPRISING SAME CRY1, CYP1A1, CYP1B1 MMP12 4358/4885MMP13 4802/4885PRKDC 4577/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.